The company's Adeno-Associated Virus platform, led by Chief Scientific Officer Fredric Manfredsson and Chairman of the Board Robert Bowser, targets brain glia and neuron cells, allowing for better distribution throughout the spinal cord and brain from a single injection. nVector also offers biomarker assays, including the first biologic diagnostic test for ALS, which sets them apart from other biotechnology companies. Additionally, Iron Horse Diagnostics, a company focused on biomarker-based ALS diagnostic tests, is developing blood-based diagnostics for ALS and prognostic assays for monitoring disease progression and testing drug effectiveness in clinical trials.